Aikema Medical Breaks Ground on Cardiac Electrophysiology Innovation Center in Shaoxing Binhai New Area

The project is located in Zhejiang Xingwan Precision Medicine Industrial Park, with a total investment of 500 million yuan, and the first phase is about 240 million yuan.For the construction of a cardiac electrophysiology-related industrial base and innovation research and development center.It is expected to build a 1300-square-meter Class 10,000 cleanroom.And set up supporting functional areas such as R&D laboratories, staff office areas, meeting rooms, and product display areas.After production starts, it can provide up to 240 job positions, with an annual output of 100,000 catheters.

The second phase plans to invest approximately 260 million yuan for the construction of a high-end medical device manufacturing center.

PFA, as a hotspot in atrial fibrillation ablation, has led AccuPulse Medical Technology Co., Ltd. to establish a research and development team headed by well-known electrophysiological technology experts since its founding. The company has received strong support from returning overseas scientists, renowned clinical experts, and venture capital institutions.To date, it has obtained 3 invention patents, 8 utility model patents, and 3 PCT applications, with a patent layout mainly focusing on areas such as voltage conversion, energy storage units, and control circuits.

Currently, the core product of the company, the PFA pulsed field ablation system, has completed all clinical enrollments.Supported by many well-known electrophysiology clinical hospitals and researchers,The long-term effectiveness at 12 months reached 87.7%, with a 100% immediate pulmonary vein isolation rate during the procedure.About 70% of patients undergo surgery under local anesthesia, while also being able to perfectly integrate with the current mainstream three-dimensional electro-anatomical mapping systems on the market, allowing clinicians to handle new technology applications with ease and proficiency.Proved its excellent clinical application value.

Scheduled to be launched in 2025 in synchronization with AccuPulse's independently developed three-dimensional cardiac mapping system, meanwhile, multiple Class III cardiac electrophysiology medical device products with independent intellectual property rights from AccuPulse are proceeding with the research and development process as planned.

As a key project in the high-end medical device industry in Binhai New Area, it will actively participate in talent program applications in the future and continuously introduce high-level professionals in the industry.Develop a PFA pulsed electric field ablation system at a leading level in China, with innovation at its core, and strive to become an internationally leading platform-based innovative technology company in the field of cardiac electrophysiology.